Belantamab mafodotin vs Ciltacabtagene autoleucel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

Belantamab mafodotin

Marketed by GlaxoSmithKline

Approved in Multiple Myelomaantibody-drug conjugate (anti-BCMA, MMAF payload)
Partial signal

NCT04246047 · Phase 3 · active, not recruiting

Patients were randomized (243 vs 251) against an active comparator and the primary endpoint of progression-free survival, assessed by an independent review committee, was met with a large separation (hazard ratio 0.41, p<0.00001). The study was open-label with no masking of participants or investigators, which keeps it below the highest grade.

Next expected readout: February 2027 · NCT05055063 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) (Up to approximately 41 months): Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5) (met)

Result source: NCT04246047

Ciltacabtagene autoleucel

Marketed by Johnson & Johnson under a licence from Legend Biotech Corporation

Approved in Multiple MyelomaCAR-T (autologous cellular therapy)
Partial signal

NCT04181827 · Phase 3 · active, not recruiting

This was a large randomized phase 3 trial against active standard therapy, and its primary endpoint, progression-free survival, clearly favoured cilta-cel (hazard ratio 0.26, P<0.001). However, it was open-label: patients and doctors knew which treatment was given, so the evidence is rated below the top level.

Next expected readout: February 2027 · NCT04133636 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)): Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023). (met)

Result source: NCT04181827

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBelantamab mafodotinCiltacabtagene autoleucel
PFS, median36.6 vs 13.4vs Daratumumabn 243NCT04246047
13 other results
  • 11.2 vs 7 n 218 · Phase 3 · primary NCT04162210
  • 3.2 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 3.9 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 2.2 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 2.8 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 3.6 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 5.7 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 5.7 2.5 mg/kg Q3W · n 29 · Phase 2 · secondary NCT05064358
  • 2.8 2.5 mg/kg Q6W · n 30 · Phase 2 · secondary NCT05064358
  • 2.5 2.5 mg/kg + 200 mg · n 28 · Phase 1/2 · secondary NCT03848845
  • 2.1 1.9 mg/kg Q3W · n 30 · Phase 2 · secondary NCT05064358
  • 2.7 1.9 mg/kg Q6W · n 34 · Phase 2 · secondary NCT05064358
  • 2.8 1.9 mg/kg Q6W · n 11 · Phase 2 · secondary NCT05064358
—Trial running · NCT05257083
OS, median24 vs 22.9vs Pomalidomide Plus Dexamethasonen 218NCT04162210
7 other results
  • 14 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 15.3 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 24.5 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 20.9 2.5 mg/kg Q3W · n 23 · Phase 2 · secondary NCT05064358
  • 13.5 2.5 mg/kg Q6W · n 25 · Phase 2 · secondary NCT05064358
  • 15 1.9 mg/kg Q3W · n 23 · Phase 2 · secondary NCT05064358
  • 14.5 1.9 mg/kg Q6W · n 21 · Phase 2 · secondary NCT05064358
27.0bn 8NCT03548207
ORR41% vs 36%vs Pomalidomide Plus Dexamethasonen 218NCT04162210
35 other results
  • 34% 3.4 mg/kg · n 99 · Phase 2 · primary NCT03525678
  • 31% 2.5 mg/kg · n 97 · Phase 2 · primary NCT03525678
  • 48% 3.4 mg/kg · n 25 · Phase 2 · primary NCT03525678
  • 30% 3.4 mg/kg · n 66 · Phase 2 · primary NCT03525678
  • 30% 2.5 mg/kg · n 64 · Phase 2 · primary NCT03525678
  • 50% 3.4 mg/kg SPLIT · n 12 · Phase 1/2 · primary NCT03544281
  • 69% 3.4 mg/kg SINGLE · n 16 · Phase 1/2 · primary NCT03544281
  • 69% 2.5mg/kg SPLIT · n 13 · Phase 1/2 · primary NCT03544281
  • 69% 2.5mg/kg SINGLE · n 16 · Phase 1/2 · primary NCT03544281
  • 92% 2.5 mg/kg Step-Down STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 75% 2.5 mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 62% 2.5 mg/kg SPLIT · n 13 · Phase 1/2 · primary NCT03544281
  • 78% 2.5 mg/kg SINGLE · n 18 · Phase 1/2 · primary NCT03544281
  • 43% 2.5 mg/kg + 200 mg · n 28 · Phase 1/2 · primary NCT03848845
  • 58% 1.9mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 50% 1.9 mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 83% 1.9 mg/kg SINGLE · n 12 · Phase 1/2 · primary NCT03544281
  • 75% 1.9mg/kg SINGLE · n 4 · Phase 1/2 · primary NCT03544281
  • 32% 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 52% 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 26% 3.4 mg/kg · n 66 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg · n 64 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 28% 2.5 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 25% 1.9 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 25% 1.9 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 43% 3.4 mg/kg + 200 mg · n 7 · Phase 1/2 · secondary NCT03848845
  • 67% 2.5 mg/kg + 200 mg · n 6 · Phase 1/2 · secondary NCT03848845
  • 18% 1.9 mg/kg Q6W · n 17 · Phase 2 · secondary NCT05064358
  • 25% 3.4 mg/kg · n 4 · Phase 1 · secondary NCT03828292
  • 50% 2.5 mg/kg · n 4 · Phase 1 · secondary NCT03828292
  • 100% 2.5 mg/kg + Bor/Dex · n 3 · Phase 1 · secondary NCT03828292
  • 50% 2.5 mg/kg + Pom/Dex · n 4 · Phase 1 · secondary NCT03828292
  • 16.7% n 6 · Phase 1 · secondary NCT04177823
97.1%bn 68NCT03548207
2 other results
VGPR or better25%b2.5 mg/kg Q3W · n 40NCT05064358
4 other results
  • 8% 2.5 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 18% 1.9 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 15% 1.9 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 18% 1.9 mg/kg Q6W · n 17 · Phase 2 · secondary NCT05064358
96.6%bn 29NCT03548207
2 other results
MRD negativity—Trial running · NCT06679101100%bn 18NCT03548207
2 other results

PFS, median

Belantamab mafodotin
36.6 vs 13.4vs Daratumumabn 243NCT04246047
13 other results
  • 11.2 vs 7 n 218 · Phase 3 · primary NCT04162210
  • 3.2 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 3.9 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 2.2 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 2.8 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 3.6 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 5.7 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 5.7 2.5 mg/kg Q3W · n 29 · Phase 2 · secondary NCT05064358
  • 2.8 2.5 mg/kg Q6W · n 30 · Phase 2 · secondary NCT05064358
  • 2.5 2.5 mg/kg + 200 mg · n 28 · Phase 1/2 · secondary NCT03848845
  • 2.1 1.9 mg/kg Q3W · n 30 · Phase 2 · secondary NCT05064358
  • 2.7 1.9 mg/kg Q6W · n 34 · Phase 2 · secondary NCT05064358
  • 2.8 1.9 mg/kg Q6W · n 11 · Phase 2 · secondary NCT05064358
Ciltacabtagene autoleucel
—Trial running · NCT05257083

OS, median

Belantamab mafodotin
24 vs 22.9vs Pomalidomide Plus Dexamethasonen 218NCT04162210
7 other results
  • 14 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 15.3 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 24.5 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 20.9 2.5 mg/kg Q3W · n 23 · Phase 2 · secondary NCT05064358
  • 13.5 2.5 mg/kg Q6W · n 25 · Phase 2 · secondary NCT05064358
  • 15 1.9 mg/kg Q3W · n 23 · Phase 2 · secondary NCT05064358
  • 14.5 1.9 mg/kg Q6W · n 21 · Phase 2 · secondary NCT05064358
Ciltacabtagene autoleucel
27.0bn 8NCT03548207

ORR

Belantamab mafodotin
41% vs 36%vs Pomalidomide Plus Dexamethasonen 218NCT04162210
35 other results
  • 34% 3.4 mg/kg · n 99 · Phase 2 · primary NCT03525678
  • 31% 2.5 mg/kg · n 97 · Phase 2 · primary NCT03525678
  • 48% 3.4 mg/kg · n 25 · Phase 2 · primary NCT03525678
  • 30% 3.4 mg/kg · n 66 · Phase 2 · primary NCT03525678
  • 30% 2.5 mg/kg · n 64 · Phase 2 · primary NCT03525678
  • 50% 3.4 mg/kg SPLIT · n 12 · Phase 1/2 · primary NCT03544281
  • 69% 3.4 mg/kg SINGLE · n 16 · Phase 1/2 · primary NCT03544281
  • 69% 2.5mg/kg SPLIT · n 13 · Phase 1/2 · primary NCT03544281
  • 69% 2.5mg/kg SINGLE · n 16 · Phase 1/2 · primary NCT03544281
  • 92% 2.5 mg/kg Step-Down STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 75% 2.5 mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 62% 2.5 mg/kg SPLIT · n 13 · Phase 1/2 · primary NCT03544281
  • 78% 2.5 mg/kg SINGLE · n 18 · Phase 1/2 · primary NCT03544281
  • 43% 2.5 mg/kg + 200 mg · n 28 · Phase 1/2 · primary NCT03848845
  • 58% 1.9mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 50% 1.9 mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 83% 1.9 mg/kg SINGLE · n 12 · Phase 1/2 · primary NCT03544281
  • 75% 1.9mg/kg SINGLE · n 4 · Phase 1/2 · primary NCT03544281
  • 32% 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 52% 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 26% 3.4 mg/kg · n 66 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg · n 64 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 28% 2.5 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 25% 1.9 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 25% 1.9 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 43% 3.4 mg/kg + 200 mg · n 7 · Phase 1/2 · secondary NCT03848845
  • 67% 2.5 mg/kg + 200 mg · n 6 · Phase 1/2 · secondary NCT03848845
  • 18% 1.9 mg/kg Q6W · n 17 · Phase 2 · secondary NCT05064358
  • 25% 3.4 mg/kg · n 4 · Phase 1 · secondary NCT03828292
  • 50% 2.5 mg/kg · n 4 · Phase 1 · secondary NCT03828292
  • 100% 2.5 mg/kg + Bor/Dex · n 3 · Phase 1 · secondary NCT03828292
  • 50% 2.5 mg/kg + Pom/Dex · n 4 · Phase 1 · secondary NCT03828292
  • 16.7% n 6 · Phase 1 · secondary NCT04177823
Ciltacabtagene autoleucel
97.1%bn 68NCT03548207
2 other results

VGPR or better

Belantamab mafodotin
25%b2.5 mg/kg Q3W · n 40NCT05064358
4 other results
  • 8% 2.5 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 18% 1.9 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 15% 1.9 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 18% 1.9 mg/kg Q6W · n 17 · Phase 2 · secondary NCT05064358
Ciltacabtagene autoleucel
96.6%bn 29NCT03548207
2 other results

MRD negativity

Belantamab mafodotin
—Trial running · NCT06679101
Ciltacabtagene autoleucel
100%bn 18NCT03548207
2 other results
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. Belantamab mafodotin: 9 of 10 rows · Ciltacabtagene autoleucel: 8 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBelantamab mafodotin
Rows use multiple source trials
Ciltacabtagene autoleucel
Rows use multiple source trials
Clinical Benefit
responder rate · % of participants
No placebo or comparator arm
38% (n=99)3.4 mg/kga,b,c,d,e
NCT03525678 · Phase 2
show 9 more doses
35% (n=66)3.4 mg/kg
NCT03525678 · Phase 2
40% (n=99)3.4 mg/kg
NCT03525678 · Phase 2
38% (n=66)3.4 mg/kg
NCT03525678 · Phase 2
60% (n=25)3.4 mg/kg
NCT03525678 · Phase 2
56% (n=25)3.4 mg/kg
NCT03525678 · Phase 2
35% (n=97)2.5 mg/kg
NCT03525678 · Phase 2
34% (n=64)2.5 mg/kg
NCT03525678 · Phase 2
36% (n=97)2.5 mg/kg
NCT03525678 · Phase 2
34% (n=64)2.5 mg/kg
NCT03525678 · Phase 2
100% (n=29)a,b,c,d,e
NCT03548207 · Phase 1/2
show 2 more doses
100% (n=9)
NCT03548207 · Phase 1/2
97.1% (n=68)
NCT03548207 · Phase 1/2
Duration of Response
time to event · months
No placebo or comparator arm
12.6 months3.4 mg/kga,b,c,d,e
NCT03525678 · Phase 2
show 9 more doses
15.9 months3.4 mg/kg
NCT03525678 · Phase 2
6.2 months3.4 mg/kg
NCT03525678 · Phase 2
15.9 months3.4 mg/kg
NCT03525678 · Phase 2
5.3 months3.4 mg/kg
NCT03525678 · Phase 2
9 months3.4 mg/kg
NCT03525678 · Phase 2
12.4 months2.5 mg/kg
NCT03525678 · Phase 2
6.9 months2.5 mg/kg
NCT03525678 · Phase 2
12.5 months2.5 mg/kg
NCT03525678 · Phase 2
11 months2.5 mg/kg
NCT03525678 · Phase 2
NA monthsa,b,c,d,e
NCT03548207 · Phase 1/2
show 2 more doses
NA months
NCT03548207 · Phase 1/2
NA months
NCT03548207 · Phase 1/2
ORR
responder rate · % of participants
No placebo or comparator arm
34% (n=99)3.4 mg/kga,b,c,d,e
NCT03525678 · Phase 2
show 9 more doses
30% (n=66)3.4 mg/kg
NCT03525678 · Phase 2
32% (n=99)3.4 mg/kg
NCT03525678 · Phase 2
26% (n=66)3.4 mg/kg
NCT03525678 · Phase 2
48% (n=25)3.4 mg/kg
NCT03525678 · Phase 2
52% (n=25)3.4 mg/kg
NCT03525678 · Phase 2
31% (n=97)2.5 mg/kg
NCT03525678 · Phase 2
30% (n=64)2.5 mg/kg
NCT03525678 · Phase 2
33% (n=97)2.5 mg/kg
NCT03525678 · Phase 2
33% (n=64)2.5 mg/kg
NCT03525678 · Phase 2
100% (n=8)a,b,c,d,e
NCT03548207 · Phase 1/2
show 1 more dose
97.1% (n=68)
NCT03548207 · Phase 1/2
Overall Survival
time to event · months
No placebo or comparator arm
14 months3.4 mg/kga,b,c,d,e
NCT03525678 · Phase 2
show 2 more doses
24.5 months3.4 mg/kg
NCT03525678 · Phase 2
15.3 months2.5 mg/kg
NCT03525678 · Phase 2
NA monthsa,b,c,d,e
NCT03548207 · Phase 1/2
show 2 more doses
27.04 months
NCT03548207 · Phase 1/2
NA months
NCT03548207 · Phase 1/2
PFS
time to event · months
No placebo or comparator arm
3.2 months3.4 mg/kga,b,c,d,e
NCT03525678 · Phase 2
show 5 more doses
3.9 months3.4 mg/kg
NCT03525678 · Phase 2
3.6 months3.4 mg/kg
NCT03525678 · Phase 2
5.7 months3.4 mg/kg
NCT03525678 · Phase 2
2.2 months2.5 mg/kg
NCT03525678 · Phase 2
2.8 months2.5 mg/kg
NCT03525678 · Phase 2
NA monthsa,b,c,d,e
NCT03548207 · Phase 1/2
show 2 more doses
NA months
NCT03548207 · Phase 1/2
NA months
NCT03548207 · Phase 1/2
VGPR or Better
responder rate · % of participants
No placebo or comparator arm
25% (n=40)2.5 mg/kg Q3Wa,b,c,e
NCT05064358 · Phase 2 · registry result, not featured evidence
show 4 more doses
8% (n=40)2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
18% (n=40)1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
15% (n=40)1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
18% (n=17)1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
96.6% (n=29)a,b,c,e
NCT03548207 · Phase 1/2
show 2 more doses
100% (n=8)
NCT03548207 · Phase 1/2
94.1% (n=68)
NCT03548207 · Phase 1/2
Dropout rate
n/a: no completion milestonef
NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3
show 56 more results
42.2%
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
n/a: no completion milestone3.4 mg/kg
NCT03525678 · Phase 2
n/a: no completion milestone3.4 mg/kg
NCT03525678 · Phase 2
—3.4 mg/kg
NCT03525678 · Phase 2
n/a: no completion milestone2.5 mg/kg
NCT03525678 · Phase 2
—2.5 mg/kg
NCT03525678 · Phase 2
75%2.5 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
80%2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
82.5%1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
77.5%1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
58.8%1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
50%3.4 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
66.7%3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
77.8%2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
69.2%2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
69.2%2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
87.5%2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
69.2%2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
75%1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
66.7%1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
42.9%3.4 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
32.1%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
25%3.4 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
0%2.5 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
—2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
33.3%
NCT04177823 · Phase 1 · registry result, not featured evidence
16.7%4.60 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
33.3%3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
25%2.50 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%1.92 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.96 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.48 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.24 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.12 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.06 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.03 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
n/a: no completion milestoneg
NCT04181827 · Phase 3 · Multiple Myeloma · phase 3
show 4 more results
n/a: no completion milestonePhase 1b (US Population)
NCT03548207 · Phase 1/2
n/a: no completion milestonePhase 2 (Japan Population)
NCT03548207 · Phase 1/2
n/a: no completion milestonePhase 2 (US Population)
NCT03548207 · Phase 1/2
n/a: no completion milestone
NCT05347485 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—f
NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3
show 56 more results
—
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
—3.4 mg/kg
NCT03525678 · Phase 2
—3.4 mg/kg
NCT03525678 · Phase 2
—3.4 mg/kg
NCT03525678 · Phase 2
—2.5 mg/kg
NCT03525678 · Phase 2
—2.5 mg/kg
NCT03525678 · Phase 2
—2.5 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
—2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
—1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
—1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
—1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
—3.4 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
—2.5 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
—2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—
NCT04177823 · Phase 1 · registry result, not featured evidence
—4.60 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—2.50 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—1.92 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.96 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.48 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.24 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.12 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.06 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.03 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—g
NCT04181827 · Phase 3 · Multiple Myeloma · phase 3
show 4 more results
—Phase 1b (US Population)
NCT03548207 · Phase 1/2
—Phase 2 (Japan Population)
NCT03548207 · Phase 1/2
—Phase 2 (US Population)
NCT03548207 · Phase 1/2
—
NCT05347485 · Phase 2 · registry result, not featured evidence
Serious AEs
50%f
NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3
show 56 more results
46.5%
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
53.5%3.4 mg/kg
NCT03525678 · Phase 2
62.5%3.4 mg/kg
NCT03525678 · Phase 2
100%3.4 mg/kg
NCT03525678 · Phase 2
45.3%2.5 mg/kg
NCT03525678 · Phase 2
100%2.5 mg/kg
NCT03525678 · Phase 2
43.6%2.5 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
53.8%2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
42.5%1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
40%1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
23.5%1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
56.3%3.4 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
72.2%2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
53.8%2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
62.5%2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
46.2%2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
25%2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
66.7%1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
66.7%1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
25%1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
33.3%1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
71.4%3.4 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
66.7%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
17.9%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
0%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
0%3.4 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
50%2.5 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
0%2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
25%2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
50%2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
0%2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
16.7%
NCT04177823 · Phase 1 · registry result, not featured evidence
50%4.60 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
33.3%3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
48.6%3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
50%3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
50%2.50 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
50%1.92 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.96 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
25%0.48 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
25%0.24 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
25%0.12 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.06 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.03 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
47.1%g
NCT04181827 · Phase 3 · Multiple Myeloma · phase 3
show 4 more results
37.9%Phase 1b (US Population)
NCT03548207 · Phase 1/2
11.1%Phase 2 (Japan Population)
NCT03548207 · Phase 1/2
61.8%Phase 2 (US Population)
NCT03548207 · Phase 1/2
51.2%
NCT05347485 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
f
thrombocytopenia 69%
vision blurred 66.1%
dry eye 50.8%
NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3
show 56 more results
vision blurred 48.4%
dry eye 37.8%
foreign body sensation in eyes 36.9%
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
3.4 mg/kg
keratopathy 74.7%
thrombocytopenia 44.4%
anaemia 36.4%
NCT03525678 · Phase 2
3.4 mg/kg
keratopathy 95.8%
fatigue 50%
anaemia 33.3%
NCT03525678 · Phase 2
3.4 mg/kg
alanine aminotransferase increased 0%
anaemia 0%
arthralgia 0%
NCT03525678 · Phase 2
2.5 mg/kg
keratopathy 70.5%
anaemia 26.3%
nausea 25.3%
NCT03525678 · Phase 2
2.5 mg/kg
alanine aminotransferase increased 0%
anaemia 0%
arthralgia 0%
NCT03525678 · Phase 2
2.5 mg/kg Q3W
vision blurred 41%
dry eye 38.5%
eye irritation 28.2%
NCT05064358 · Phase 2 · registry result, not featured evidence
2.5 mg/kg Q6W
vision blurred 46.2%
thrombocytopenia 33.3%
anaemia 30.8%
NCT05064358 · Phase 2 · registry result, not featured evidence
1.9 mg/kg Q3W
thrombocytopenia 42.5%
anaemia 30%
dry eye 30%
NCT05064358 · Phase 2 · registry result, not featured evidence
1.9 mg/kg Q6W
anaemia 37.5%
dry eye 30%
eye irritation 27.5%
NCT05064358 · Phase 2 · registry result, not featured evidence
1.9 mg/kg Q6W
vision blurred 52.9%
dry eye 47.1%
eye irritation 29.4%
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
3.4 mg/kg SINGLE
keratopathy 93.8%
thrombocytopenia 56.3%
neuropathy peripheral 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
3.4 mg/kg SPLIT
keratopathy 83.3%
thrombocytopenia 75%
fatigue 41.7%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
3.4 mg/kg SPLIT
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg SINGLE
keratopathy 83.3%
vision blurred 66.7%
platelet count decreased 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg SPLIT
keratopathy 76.9%
thrombocytopenia 69.2%
vision blurred 38.5%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg STRETCH
keratopathy 100%
platelet count decreased 58.3%
gamma-glutamyltransferase increased 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg Step-Down STRETCH
keratopathy 100%
platelet count decreased 58.3%
diarrhoea 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5mg/kg SINGLE
keratopathy 68.8%
fatigue 43.8%
thrombocytopenia 43.8%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5mg/kg SPLIT
keratopathy 92.3%
vision blurred 53.8%
diarrhoea 46.2%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg SINGLE
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg SPLIT
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg Step-Down STRETCH
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5mg/kg SINGLE
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5mg/kg SPLIT
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9 mg/kg SINGLE
keratopathy 91.7%
platelet count decreased 75%
constipation 66.7%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9 mg/kg STRETCH
keratopathy 75%
diarrhoea 50%
platelet count decreased 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9mg/kg SINGLE
diarrhoea 75%
keratopathy 75%
abdominal pain 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9mg/kg STRETCH
keratopathy 75%
diarrhoea 41.7%
insomnia 41.7%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9 mg/kg SINGLE
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9 mg/kg STRETCH
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9mg/kg SINGLE
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9mg/kg STRETCH
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
3.4 mg/kg + 200 mg
keratopathy 85.7%
pyrexia 57.1%
anaemia 42.9%
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg + 200 mg
keratopathy 100%
anaemia 66.7%
blepharitis 50%
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg + 200 mg
keratopathy 71.4%
pyrexia 35.7%
vision blurred 35.7%
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg + 200 mg
alanine aminotransferase increased 0%
anaemia 0%
arthralgia 0%
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
3.4 mg/kg
diarrhoea 50%
enterocolitis 50%
headache 50%
NCT03828292 · Phase 1 · registry result, not featured evidence
2.5 mg/kg
platelet count decreased 100%
alanine aminotransferase increased 50%
aspartate aminotransferase increased 50%
NCT03828292 · Phase 1 · registry result, not featured evidence
2.5 mg/kg + Bor/Dex
thrombocytopenia 100%
diarrhoea 66.7%
insomnia 66.7%
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
2.5 mg/kg + Pom/Dex
constipation 50%
neutrophil count decreased 50%
oedema peripheral 50%
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
2.5 mg/kg + Bor/Dex
abdominal pain upper 0%
abnormal faeces 0%
alanine aminotransferase increased 0%
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
2.5 mg/kg + Pom/Dex
abdominal pain upper 0%
abnormal faeces 0%
alanine aminotransferase increased 0%
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
blood lactate dehydrogenase increased 66.7%
hyponatraemia 66.7%
lymphocyte count decreased 66.7%
NCT04177823 · Phase 1 · registry result, not featured evidence
4.60 mg/kg
thrombocytopenia 83.3%
aspartate aminotransferase increased 66.7%
fatigue 66.7%
NCT02064387 · Phase 1 · registry result, not featured evidence
3.40 mg/kg
vision blurred 100%
aspartate aminotransferase increased 66.7%
chills 66.7%
NCT02064387 · Phase 1 · registry result, not featured evidence
3.40 mg/kg
vision blurred 51.4%
cough 40%
aspartate aminotransferase increased 37.1%
NCT02064387 · Phase 1 · registry result, not featured evidence
3.40 mg/kg
vision blurred 33.3%
anaemia 16.7%
blood creatine phosphokinase increased 16.7%
NCT02064387 · Phase 1 · registry result, not featured evidence
2.50 mg/kg
anaemia 37.5%
fatigue 37.5%
nausea 37.5%
NCT02064387 · Phase 1 · registry result, not featured evidence
1.92 mg/kg
nausea 75%
vision blurred 75%
chills 50%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.96 mg/kg
anaemia 66.7%
fatigue 66.7%
chills 33.3%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.48 mg/kg
arthralgia 50%
back pain 25%
decreased appetite 25%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.24 mg/kg
fatigue 50%
nausea 50%
anaemia 25%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.12 mg/kg
cough 50%
hypercalcaemia 50%
nausea 50%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.06 mg/kg
anaemia 100%
diarrhoea 100%
hyperuricaemia 100%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.03 mg/kg
fatigue 100%
neutropenia 100%
osteonecrosis of jaw 100%
NCT02064387 · Phase 1 · registry result, not featured evidence
g
neutropenia 89.9%
cytokine release syndrome 62%
thrombocytopenia 54.3%
NCT04181827 · Phase 3 · Multiple Myeloma · phase 3
show 4 more results
neutropenia 100%
cytokine release syndrome 89.7%
thrombocytopenia 86.2%
NCT03548207 · Phase 1/2
neutropenia 88.9%
cytokine release syndrome 77.8%
thrombocytopenia 77.8%
NCT03548207 · Phase 1/2
neutropenia 94.1%
cytokine release syndrome 86.8%
anaemia 83.8%
NCT03548207 · Phase 1/2
neutropenia 80.5%
anaemia 59.8%
cytokine release syndrome 57.3%
NCT05347485 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 1/2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eThe assessment timepoint is not available for both results.
  6. fPopulation comparability has not been reviewed for 55 of these studies.
  7. gPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Belantamab mafodotin

Overall Survival 24 vs 22.9 Pomalidomide Plus Dexamethasone months
time to event · months
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
ORR 41% (n=218) vs 36% (n=107) Pomalidomide Plus Dexamethasone
responder rate · % of participants
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
Clinical Benefit 47% (n=218) vs 47% (n=107) Pomalidomide Plus Dexamethasone
responder rate · % of participants
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
Duration of Response 25.3 vs 9.9 Pomalidomide Plus Dexamethasone months
time to event · months
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
Time to Response 2.1 vs 1.53 Pomalidomide Plus Dexamethasone months
time to event · months
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
Time to Progression 11.3 vs 8.6 Pomalidomide Plus Dexamethasone months
time to event · months
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
MRD Negativity 10.1% (n=218) vs 0.9% (n=107) Pomalidomide Plus Dexamethasone
event count · % of participants
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3 · converted to % from 22 Participants as posted
Time to Response 1.5 months3.4 mg/kg
time to event · months
No placebo or comparator arm
NCT03525678 · Phase 2
show 15 more results
0.9 months3.4 mg/kg
NCT03525678 · Phase 2
1.5 months3.4 mg/kg
NCT03525678 · Phase 2
1.4 months3.4 mg/kg
NCT03525678 · Phase 2
0.9 months3.4 mg/kg
NCT03525678 · Phase 2
1.4 months3.4 mg/kg
NCT03525678 · Phase 2
1.5 months2.5 mg/kg
NCT03525678 · Phase 2
1.4 months2.5 mg/kg
NCT03525678 · Phase 2
1.5 months2.5 mg/kg
NCT03525678 · Phase 2
1.5 months2.5 mg/kg
NCT03525678 · Phase 2
0.8 months2.5 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
0.7 months2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
0.7 months2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
1.1 months1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
0.8 months1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
1.5 months1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
Time to Progression 3.9 months3.4 mg/kg
time to event · months
No placebo or comparator arm
NCT03525678 · Phase 2
show 11 more results
3.6 months3.4 mg/kg
NCT03525678 · Phase 2
4.9 months3.4 mg/kg
NCT03525678 · Phase 2
5.7 months3.4 mg/kg
NCT03525678 · Phase 2
2.2 months2.5 mg/kg
NCT03525678 · Phase 2
2.9 months2.5 mg/kg
NCT03525678 · Phase 2
6 months2.5 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
2.8 months2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
2.5 months2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
2.1 months1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
2.7 months1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
2.9 months1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Global Health Status -4.1 score @ 7wk3.4 mg/kg
absolute change · score
No placebo or comparator arm
GHS/QoL,Week 07,n=48,47,17
NCT03525678 · Phase 2
show 2 more results
1.5 score @ 7wk3.4 mg/kg
GHS/QoL,Week 07,n=48,47,17
NCT03525678 · Phase 2
-0.7 score @ 7wk2.5 mg/kg
GHS/QoL,Week 07,n=48,47,17
NCT03525678 · Phase 2
EORTC QLQ-C30 Global Health Status 6 score @ 13wk3.4 mg/kg
absolute change · score
No placebo or comparator arm
GHS/QoL,Week 13,n=29,29,16
NCT03525678 · Phase 2
show 2 more results
1 score @ 13wk3.4 mg/kg
GHS/QoL,Week 13,n=29,29,16
NCT03525678 · Phase 2
-3.2 score @ 13wk2.5 mg/kg
GHS/QoL,Week 13,n=29,29,16
NCT03525678 · Phase 2
EORTC QLQ-C30 Global Health Status 3.7 score @ 19wk3.4 mg/kg
absolute change · score
No placebo or comparator arm
GHS/QoL,Week 19,n=19,27,10
NCT03525678 · Phase 2
show 2 more results
0 score @ 19wk3.4 mg/kg
GHS/QoL,Week 19,n=19,27,10
NCT03525678 · Phase 2
-2.2 score @ 19wk2.5 mg/kg
GHS/QoL,Week 19,n=19,27,10
NCT03525678 · Phase 2

+ 304 further endpoints in the CSV export.

Ciltacabtagene autoleucel

MRD Negative 100% (n=18)
responder rate · % of participants
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 2 more results
89.7% (n=39)
NCT03548207 · Phase 1/2
75% (n=8)
NCT03548207 · Phase 1/2
Time to First Response 0.95 months
time to event · months
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 2 more results
0.95 months
NCT03548207 · Phase 1/2
0.92 months
NCT03548207 · Phase 1/2
EQ-5D-5L Utility -0.1 score @ 1wk
absolute change · score
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 27 more results
0 score @ 4wk
NCT03548207 · Phase 1/2
0 score @ 8wk
NCT03548207 · Phase 1/2
0 score @ 11.14wk
NCT03548207 · Phase 1/2
0 score @ 14.29wk
NCT03548207 · Phase 1/2
0 score @ 18.29wk
NCT03548207 · Phase 1/2
0 score @ 22.29wk
NCT03548207 · Phase 1/2
0 score @ 26.29wk
NCT03548207 · Phase 1/2
0.1 score @ 30.29wk
NCT03548207 · Phase 1/2
0.1 score @ 34.29wk
NCT03548207 · Phase 1/2
0.1 score @ 38.29wk
NCT03548207 · Phase 1/2
0.1 score @ 42.29wk
NCT03548207 · Phase 1/2
0 score @ 46.29wk
NCT03548207 · Phase 1/2
0.1 score @ 50.29wk
NCT03548207 · Phase 1/2
-0.1 score @ 54.29wk
NCT03548207 · Phase 1/2
-0.05 score @ 1wk
NCT03548207 · Phase 1/2
-0.06 score @ 4wk
NCT03548207 · Phase 1/2
-0.03 score @ 8wk
NCT03548207 · Phase 1/2
0.01 score @ 11.14wk
NCT03548207 · Phase 1/2
-0.04 score @ 14.29wk
NCT03548207 · Phase 1/2
0 score @ 18.29wk
NCT03548207 · Phase 1/2
-0.02 score @ 22.29wk
NCT03548207 · Phase 1/2
-0.01 score @ 26.29wk
NCT03548207 · Phase 1/2
0.04 score @ 30.29wk
NCT03548207 · Phase 1/2
0.05 score @ 34.29wk
NCT03548207 · Phase 1/2
0.07 score @ 38.29wk
NCT03548207 · Phase 1/2
0.04 score @ 42.29wk
NCT03548207 · Phase 1/2
0.14 score @ 46.29wk
NCT03548207 · Phase 1/2
EQ-5D-5L VAS -6.7 score @ 1wk
absolute change · score
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 27 more results
0.6 score @ 4wk
NCT03548207 · Phase 1/2
2.2 score @ 8wk
NCT03548207 · Phase 1/2
5.3 score @ 11.14wk
NCT03548207 · Phase 1/2
1.9 score @ 14.29wk
NCT03548207 · Phase 1/2
6.4 score @ 18.29wk
NCT03548207 · Phase 1/2
4.8 score @ 22.29wk
NCT03548207 · Phase 1/2
6.1 score @ 26.29wk
NCT03548207 · Phase 1/2
9.6 score @ 30.29wk
NCT03548207 · Phase 1/2
11 score @ 34.29wk
NCT03548207 · Phase 1/2
7.2 score @ 38.29wk
NCT03548207 · Phase 1/2
10 score @ 42.29wk
NCT03548207 · Phase 1/2
11.9 score @ 46.29wk
NCT03548207 · Phase 1/2
10.2 score @ 50.29wk
NCT03548207 · Phase 1/2
-2 score @ 54.29wk
NCT03548207 · Phase 1/2
-13.75 score @ 1wk
NCT03548207 · Phase 1/2
-0.75 score @ 4wk
NCT03548207 · Phase 1/2
-4.5 score @ 8wk
NCT03548207 · Phase 1/2
-3 score @ 11.14wk
NCT03548207 · Phase 1/2
-1.88 score @ 14.29wk
NCT03548207 · Phase 1/2
0 score @ 18.29wk
NCT03548207 · Phase 1/2
0 score @ 22.29wk
NCT03548207 · Phase 1/2
-0.25 score @ 26.29wk
NCT03548207 · Phase 1/2
2.5 score @ 30.29wk
NCT03548207 · Phase 1/2
0 score @ 34.29wk
NCT03548207 · Phase 1/2
-2.5 score @ 38.29wk
NCT03548207 · Phase 1/2
-12.5 score @ 42.29wk
NCT03548207 · Phase 1/2
-10 score @ 46.29wk
NCT03548207 · Phase 1/2
PGI-S -0.3 score @ 1wk
absolute change · score
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 27 more results
0.3 score @ 1wk
NCT03548207 · Phase 1/2
-0.3 score @ 4wk
NCT03548207 · Phase 1/2
-0.1 score @ 4wk
NCT03548207 · Phase 1/2
-0.3 score @ 8wk
NCT03548207 · Phase 1/2
0.3 score @ 8wk
NCT03548207 · Phase 1/2
-0.3 score @ 11.14wk
NCT03548207 · Phase 1/2
0 score @ 11.14wk
NCT03548207 · Phase 1/2
-0.3 score @ 14.29wk
NCT03548207 · Phase 1/2
0 score @ 14.29wk
NCT03548207 · Phase 1/2
-0.3 score @ 18.29wk
NCT03548207 · Phase 1/2
0 score @ 18.29wk
NCT03548207 · Phase 1/2
-0.4 score @ 22.29wk
NCT03548207 · Phase 1/2
0 score @ 22.29wk
NCT03548207 · Phase 1/2
-0.3 score @ 26.29wk
NCT03548207 · Phase 1/2
0.3 score @ 26.29wk
NCT03548207 · Phase 1/2
-0.2 score @ 30.29wk
NCT03548207 · Phase 1/2
0 score @ 30.29wk
NCT03548207 · Phase 1/2
-0.3 score @ 34.29wk
NCT03548207 · Phase 1/2
0 score @ 34.29wk
NCT03548207 · Phase 1/2
-0.5 score @ 38.29wk
NCT03548207 · Phase 1/2
0 score @ 38.29wk
NCT03548207 · Phase 1/2
-0.2 score @ 42.29wk
NCT03548207 · Phase 1/2
0 score @ 42.29wk
NCT03548207 · Phase 1/2
-0.6 score @ 46.29wk
NCT03548207 · Phase 1/2
0 score @ 46.29wk
NCT03548207 · Phase 1/2
-0.9 score @ 50.29wk
NCT03548207 · Phase 1/2
-0.5 score @ 54.29wk
NCT03548207 · Phase 1/2
PGIC 2.7 score @ 4wk
absolute value · score
No placebo or comparator arm
NCT03548207 · Phase 1/2
show 7 more results
2.8 score @ 4wk
NCT03548207 · Phase 1/2
2.5 score @ 8wk
NCT03548207 · Phase 1/2
2.9 score @ 8wk
NCT03548207 · Phase 1/2
2.2 score @ 11.14wk
NCT03548207 · Phase 1/2
2.5 score @ 11.14wk
NCT03548207 · Phase 1/2
2 score @ 14.29wk
NCT03548207 · Phase 1/2
2.4 score @ 14.29wk
NCT03548207 · Phase 1/2
Partial 9.8% (n=82)
responder rate · % of participants
No placebo or comparator arm
NCT05347485 · Phase 2 · registry result, not featured evidence
VGPR 14.6% (n=82)
responder rate · % of participants
No placebo or comparator arm
NCT05347485 · Phase 2 · registry result, not featured evidence
Complete 17.1% (n=82)
responder rate · % of participants
No placebo or comparator arm
NCT05347485 · Phase 2 · registry result, not featured evidence
sCR 15.9% (n=82)
responder rate · % of participants
No placebo or comparator arm
NCT05347485 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Belantamab mafodotin's landscape · Ciltacabtagene autoleucel's landscape